BiomX Inc. (PHGE) announced a 1‑for‑19 reverse stock split of its common shares, effective at the opening of the market on November 25, 2025. The action will reduce the number of outstanding shares from roughly 29 million to about 1.5 million and will change the company’s CUSIP to 09090D 509. All equity awards, warrants and convertible preferred stock will be adjusted proportionally, while the par value and authorized share count remain unchanged.
The reverse split is intended to lift the per‑share price above the minimum threshold required by the Nasdaq and to improve liquidity for institutional investors. BiomX’s share price has been trading near its 52‑week low and has fallen sharply over the past year, prompting the board to seek a consolidation that may help the company avoid a potential delisting.
BiomX is a clinical‑stage biotechnology company focused on phage‑based therapies. Its pipeline includes candidates BX004 for cystic fibrosis and BX011 for diabetic foot infections, with recent Phase 2 data for BX211 and ongoing patient dosing for BX004. The company reported a net loss of $9.2 million in Q3 2025, compared with a net income of $9.6 million in Q3 2024, and a cash balance of $8.1 million as of September 30, 2025. Management indicated that the cash position is expected to fund operations through Q1 2026, but additional financing or partnerships will likely be required.
The reverse split follows a prior 10‑for‑1 consolidation in August 2024, underscoring a pattern of actions aimed at maintaining compliance with exchange listing rules. While the split does not alter ownership percentages except for fractional rounding, it signals to investors that the company is actively managing its capital structure in response to market pressures.
Investors reacted with concern that a reverse split may signal financial distress, reflecting the volatility surrounding the event.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.